FPS
GRCL

Fieldpoint Private Securities’s Gracell Biotechnologies Inc. American Depositary Shares GRCL Stock Holding History

Fieldpoint Private Securities’s Portfolio GRCL Stock Details GRCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-160
Closed -$1K – 1759
2021
Q4 		$1K Buy
+160
New +$1.54K ﹤0.01% 1629

Other funds holding GRCL

Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
CII
Capital International Inc Los Angeles, California $14.3B AUM 34.19% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

Fieldpoint Private Securities's GRCL Position: Q1 2022 in Review

Fieldpoint Private Securities sold out of Gracell Biotechnologies Inc. American Depositary Shares (GRCL) in Q1 2022, closing a stake of 160 shares — an estimated $1K sold.

Fieldpoint Private Securities first reported a position in GRCL in Q4 2021 and held it in 1 quarter. The position peaked at $1K in Q4 2021. 34 funds tracked by Wall St. Rank hold GRCL as of Q1 2022.

  • Fieldpoint Private Securities reported no remaining Gracell Biotechnologies Inc. American Depositary Shares position as of Q1 2022 after selling out during the quarter.
  • Fieldpoint Private Securities sold 160 Gracell Biotechnologies Inc. American Depositary Shares shares in Q1 2022, an estimated $1K.
  • Fieldpoint Private Securities first reported a position in Gracell Biotechnologies Inc. American Depositary Shares in Q4 2021 and held it in 1 quarter.
  • Fieldpoint Private Securities's Gracell Biotechnologies Inc. American Depositary Shares position peaked at $1K in Q4 2021.
  • 34 funds tracked by Wall St. Rank held Gracell Biotechnologies Inc. American Depositary Shares as of Q1 2022.

Based on Fieldpoint Private Securities's 13F filing for Q1 2022, filed 7 Apr 2022.